SER100 in Isolated Systolic Hypertension
Primary Purpose
Isolated Systolic Hypertension
Status
Completed
Phase
Phase 2
Locations
International
Study Type
Interventional
Intervention
SER100
Placebo
Sponsored by

About this trial
This is an interventional treatment trial for Isolated Systolic Hypertension
Eligibility Criteria
Inclusion Criteria:
- Mean systolic blood pressure ≥ 150 mmHg and mean diastolic blood pressure < 90 mmHg - as determined by daytime continuous ambulatory blood pressure measurement (ABPM)
- Male or female
- Age 50-80 years (both inclusive) at screening
- Patients must be on stable doses with one or more antihypertensives
- BMI <32 kg/m2
- Written informed consent
Exclusion Criteria:
- Acute myocardial infarction in the last 6 months before screening
- Stroke in the last 6 months before screening
- Uncompensated heart failure (NYHA Class IV)
- Angina pectoris with an anticipated need for administration of short-acting nitrates
- Known, severe sleep apnoea
- Abnormal laboratory values (i.e. > 2 x upper normal limit) at screening
- Subjects working night shifts (11 PM to 7 AM)
- Participation in any other clinical trial with an investigational medicinal product or device within 1 month prior to randomisation.
- Subjects with upper arm circumference ≤24 cm or ≥ 42 cm.
- Any general condition, serious disease or current evidence of any mental or physical disorder or collaboration attitude (e.g. dementia, substance abuse) which, in the judgment of the investigator makes the subject unsuitable for enrollment, and/or may interfere with the study evaluations or affect subject's safety and/or may cause risk for poor protocol compliance
- Pregnant or lactating women.
- Female subjects of childbearing potential, or male subjects whose female partner (unless post-menopausal for 1 year or surgically sterile) is unwilling to use adequate contraceptive measures throughout the duration of the study
Sites / Locations
- FinnMedi Oy/Valkeakoski District Hospital
- CRST/Turku University Hospital
- Semmelweiss University Hospital
- Medi3 Innlandet
- Ulleval University Hospital
- Northwick Park Hospital
- Brighton and Sussex University Hospital
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
SER100
Placebo
Arm Description
SER100 10 mg s.c. twice daily
Placebo administered s.c. twice daily
Outcomes
Primary Outcome Measures
Number of participants with adverse events
Secondary Outcome Measures
Change from baseline in systolic blood pressure
Full Information
NCT ID
NCT01987284
First Posted
November 5, 2013
Last Updated
October 19, 2016
Sponsor
Serodus AS
Collaborators
Smerud Medical Research International AS, The Research Council of Norway
1. Study Identification
Unique Protocol Identification Number
NCT01987284
Brief Title
SER100 in Isolated Systolic Hypertension
Official Title
A Randomized, Double-blind, Placebo-controlled, Cross-over, Multi-center Study Assessing the Safety, Tolerability and Efficacy of SER100 10 mg s.c. Twice Daily for 2 Days in Patients With Isolated Systolic Hypertension Insufficiently Treated With One or More Anti-hypertensives.
Study Type
Interventional
2. Study Status
Record Verification Date
October 2016
Overall Recruitment Status
Completed
Study Start Date
October 2013 (undefined)
Primary Completion Date
July 2014 (Actual)
Study Completion Date
September 2014 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Serodus AS
Collaborators
Smerud Medical Research International AS, The Research Council of Norway
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
Isolated Systolic Hypertension (ISH)is the dominating hypertensive disease in elderly people. Much attention has recently been drawn to the strong relationship between the systolic blood pressure and cardiovascular morbidity.
In previous clinical studies carried out in individuals with normal blood pressure at baseline SER100 decreased primarily the systolic blood pressure. It is hypothesized that the effect on systolic blood pressure in hypertensive patients will be larger or equal to the fall seen in normotensive patients.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Isolated Systolic Hypertension
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Crossover Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
17 (Actual)
8. Arms, Groups, and Interventions
Arm Title
SER100
Arm Type
Experimental
Arm Description
SER100 10 mg s.c. twice daily
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Placebo administered s.c. twice daily
Intervention Type
Drug
Intervention Name(s)
SER100
Intervention Type
Drug
Intervention Name(s)
Placebo
Primary Outcome Measure Information:
Title
Number of participants with adverse events
Time Frame
Up to 4 weeks
Secondary Outcome Measure Information:
Title
Change from baseline in systolic blood pressure
Time Frame
Up to 4 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
50 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Mean systolic blood pressure ≥ 150 mmHg and mean diastolic blood pressure < 90 mmHg - as determined by daytime continuous ambulatory blood pressure measurement (ABPM)
Male or female
Age 50-80 years (both inclusive) at screening
Patients must be on stable doses with one or more antihypertensives
BMI <32 kg/m2
Written informed consent
Exclusion Criteria:
Acute myocardial infarction in the last 6 months before screening
Stroke in the last 6 months before screening
Uncompensated heart failure (NYHA Class IV)
Angina pectoris with an anticipated need for administration of short-acting nitrates
Known, severe sleep apnoea
Abnormal laboratory values (i.e. > 2 x upper normal limit) at screening
Subjects working night shifts (11 PM to 7 AM)
Participation in any other clinical trial with an investigational medicinal product or device within 1 month prior to randomisation.
Subjects with upper arm circumference ≤24 cm or ≥ 42 cm.
Any general condition, serious disease or current evidence of any mental or physical disorder or collaboration attitude (e.g. dementia, substance abuse) which, in the judgment of the investigator makes the subject unsuitable for enrollment, and/or may interfere with the study evaluations or affect subject's safety and/or may cause risk for poor protocol compliance
Pregnant or lactating women.
Female subjects of childbearing potential, or male subjects whose female partner (unless post-menopausal for 1 year or surgically sterile) is unwilling to use adequate contraceptive measures throughout the duration of the study
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Helga Gudmundsdottir, MD
Organizational Affiliation
Oslo University Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
FinnMedi Oy/Valkeakoski District Hospital
City
Tampere
Country
Finland
Facility Name
CRST/Turku University Hospital
City
Turku
Country
Finland
Facility Name
Semmelweiss University Hospital
City
Budapest
Country
Hungary
Facility Name
Medi3 Innlandet
City
Hamar
ZIP/Postal Code
2317
Country
Norway
Facility Name
Ulleval University Hospital
City
Oslo
ZIP/Postal Code
0450
Country
Norway
Facility Name
Northwick Park Hospital
City
Harrow
State/Province
Middlesex
ZIP/Postal Code
HA1 3UJ
Country
United Kingdom
Facility Name
Brighton and Sussex University Hospital
City
Brighton
Country
United Kingdom
12. IPD Sharing Statement
Learn more about this trial
SER100 in Isolated Systolic Hypertension
We'll reach out to this number within 24 hrs